Sanofi-aventis is one of the world's leading pharmaceutical companies and number 1 in Europe.
 
Present in more than 100 countries, with around 11,000 scientists, we have around 100,000 employees working to improve health and wellbeing. Our Global headquarters are in Paris, France and our local headquarters are in Dublin, Ireland.

Sanofi-aventis focuses its activities on these major therapeutic areas:

• Cardiovascular
• Central Nervous System
• Metabolic Disorders
• Oncology
• Thrombosis 
• Internal Medicine 
• Vaccines 
  

The sanofi-aventis portfolio of marketed products includes several medicines that are world leaders in their respective classes, in the areas of thrombosis, cardiovascular disease, sleep disorders, epilepsy, diabetes and cancer. 
 
In Ireland, sanofi-aventis markets

• Actonel® (risedronate sodium),
• Clexane® (enoxaparin sodium),
• Plavix® (clopidogrel bisulfate),
• Aprovel® (irbesartan),
• Lantus® (insulin glargine),
• Taxotere® (docetaxel),
• Stilnoct® (zolpidem tartrate),
• Copaxone® (glatiramer acetate),
• Xatral® (alfuzosine)
• and Tritace® (ramipril)    

amongst other products.

The foundation of sanofi-aventis's worldwide growth is a highly productive and innovative R&D organization with about 11,000 scientists working in more than 20 research centres in three continents to create innovative therapeutic treatments. Around thirty R&D projects are currently in advanced stages of development. 
 
 
For more information about sanofi-aventis worldwide, visit www.sanofi-aventis.com.